Correct Answer: C. Buprenorphine
Buprenorphine is the gold-standard maintenance therapy for opioid use disorder (OUD) in India and globally. As a partial μ-opioid agonist, buprenorphine produces a ceiling effect on respiratory depression, making it safer than full agonists like methadone—a critical advantage in resource-limited Indian settings where overdose monitoring is challenging. During the maintenance phase (weeks 2–4 onwards after acute withdrawal), buprenorphine prevents craving and withdrawal symptoms by occupying opioid receptors without producing euphoria, thus reducing illicit drug-seeking behavior. The typical maintenance dose is 8–16 mg/day (sublingual), often combined with naloxone (Suboxone) to deter intravenous misuse. Unlike acute withdrawal management (which uses clonidine or lofexidine for sympathomimetic symptoms), maintenance therapy requires a long-acting opioid agonist to sustain neurochemical stability. Buprenorphine's high receptor affinity and long half-life (24–72 hours) allow once-daily or alternate-day dosing, improving adherence in Indian outpatient addiction centers. NACO and AIIMS guidelines recommend buprenorphine as first-line maintenance for OUD, particularly in opioid-dependent individuals with comorbid hepatitis C (common in Indian PWID populations) due to its favorable hepatic metabolism profile.
Why the other options are wrong
A. Disulfiram — Disulfiram is an aldehyde dehydrogenase inhibitor used exclusively for alcohol use disorder maintenance (aversion therapy), not opioid withdrawal or maintenance. It has no role in opioid pharmacotherapy and would not prevent opioid craving or withdrawal. NBE may pair it here to test whether students confuse maintenance therapy across different substance use disorders. B. Butorphanol — Butorphanol is a mixed opioid agonist-antagonist (κ-agonist, μ-antagonist) used for acute pain, not maintenance therapy. It can precipitate withdrawal in opioid-dependent individuals and lacks the sustained agonist activity needed for maintenance. Its short half-life (~3 hours) and antagonist properties make it unsuitable for preventing craving during the maintenance phase. D. Clonidine — Clonidine is an α₂-adrenergic agonist used for acute opioid withdrawal (managing sympathomimetic symptoms: anxiety, sweating, tachycardia) over 7–10 days, not maintenance. It addresses withdrawal discomfort but does not prevent craving or provide long-term neurochemical stability. Maintenance requires an opioid agonist, not a sympatholytic agent.
High-Yield Facts
- Buprenorphine is a partial μ-opioid agonist with a ceiling effect on respiratory depression, making it safer than methadone in overdose.
- Maintenance phase of opioid withdrawal begins at week 2–4 after acute withdrawal resolution and requires long-acting opioid agonist therapy.
- Buprenorphine maintenance dose: 8–16 mg/day sublingual; half-life 24–72 hours allows once-daily or alternate-day dosing.
- Clonidine (α₂-agonist) is used for acute withdrawal (days 1–10) to manage sympathomimetic symptoms, not maintenance.
- Buprenorphine + naloxone (Suboxone) is preferred over buprenorphine alone to reduce intravenous misuse in Indian addiction centers.
- NACO/AIIPS guidelines recommend buprenorphine as first-line maintenance for OUD, especially in hepatitis C co-infected PWID.
Mnemonics
OUD Maintenance = BUPRENORPHINE (Partial Agonist) Buprenorphine = Best for maintenance (partial agonist, ceiling effect, safe). Methadone = Maintenance alternative (full agonist, higher overdose risk). Clonidine = Crisis/acute withdrawal only (sympatholytic, not agonist). Phases of Opioid Withdrawal Management ACUTE (Days 1–10): Clonidine (sympathomimetic control). MAINTENANCE (Weeks 2–4+): Buprenorphine or methadone (prevent craving, long-term stability). Remember: Acute = symptom relief; Maintenance = receptor occupancy.
NBE Trap
NBE pairs clonidine (acute withdrawal agent) with buprenorphine (maintenance agent) to test whether students conflate the two phases of opioid withdrawal management. Students who memorize "clonidine for opioid withdrawal" without distinguishing acute vs. maintenance phases will select the wrong answer.
Clinical Pearl
In Indian addiction centers, buprenorphine maintenance is often initiated after 48–72 hours of acute withdrawal (using clonidine), then continued for months to years. A patient on buprenorphine 12 mg/day will not experience euphoria from additional opioid use (ceiling effect), making it ideal for harm reduction in high-relapse-risk populations like street-based PWID in metropolitan India.
_Reference: KD Tripathi Pharmacology Ch. 32 (Opioid Agonists & Antagonists); Harrison's Principles of Internal Medicine Ch. 474 (Opioid Use Disorder); NACO Guidelines on Opioid Substitution Therapy in India_